46 results about "Organ dysfunction" patented technology

The invention relates to the technical field of data processing, and discloses an old-age multi-organ function decline rehabilitation prediction method and system based on artificial intelligence. The method comprises the following steps: screening cardiovascular, respiratory, renal function and liver function indexes of an elderly patient through a multi-source data quality evaluation matrix, carrying out time sequence synchronization according to visceral organ physiology time delay characteristics, adopting a visceral organ function correlation positioning analysis algorithm to identify a collaborative decline mode and calculating 1-NN similarity and Max-NN correlation decline degree, and finally, inputting target patient data into a special prediction model of a corresponding hierarchical group to generate a rehabilitation prediction result. According to the method and the device, the technical problem that an existing senile multi-organ function decline prediction method lacks parameter-free collaborative decline mode recognition and individualized layered prediction is solved.

The invention discloses a sepsis patient organ function damage early warning judgment method based on machine learning, and the method comprises the steps: obtaining the multi-modal clinical data of a sepsis patient, including vital sign time sequence data, inspection data, treatment intervention data and static patient basic information; after data standardization processing, organ function associated features are extracted through a multi-scale feature fusion strategy, and an organ-level feature set is constructed; the method comprises the following steps of: obtaining a multi-organ collaborative early warning model, inputting the multi-organ collaborative early warning model into a pre-trained multi-organ collaborative early warning model, respectively constructing an inter-organ compensatory relation map by double branches of the model, quantifying organ injury risk contribution degree, and outputting a multi-organ functional injury risk matrix by combining with attention mechanism weighted fusion; and generating an early warning result based on the risk matrix and the organ specificity early warning threshold, including the injury risk level of each organ and the dominant risk key feature identifier, monitoring data update in real time, and dynamically adjusting the interval to update the early warning result. According to the invention, the limitation of traditional single-source data and single-organ early warning is broken through, and the early warning accuracy and real-time performance are improved.

Subject matter of the present invention is an anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold for use in therapy of a chronical or acute disease or acute condition of a patient for prevention or reduction of organ dysfunction or organ failure. In a preferred embodiment subject matter of the invention is an anti-ADM antibody or an anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold for use in therapy of a chronical or acute disease or acute condition of a patient for prevention or reduction of kidney dysfunction or kidney failure or liver dysfunction or liver failure.

A system and method is disclosed for measuring muscle reflexes (e.g., a bulbocavernosus reflex) as a tool for identifying / diagnosing dysfunctions (e.g., spinal cord abnormalities, bladder voiding dysfunction, and sexual organ dysfunction) non-invasively by using mechanical stimulation. The system and method includes a probe having a predetermined patient contacting portion, wherein when the contacting portion is moved into contact with a particular area of the patient (e.g., the patient's genitals), the contact induces a muscle reflex. The probe detects the pressure resulting from the contacting portion being abruptly and forcibly brought into contact with the particular area. Such detection is used to electronically initiate capture of electrical responses from a plurality of electrodes placed on the patient's skin in proximity to the particular area. Such electrical responses are processed to determine characteristics of the patient's reflexes of one or more muscles adjacent to the electrodes.

Systems and methods for the detection of sepsis and treatment of patients. A sepsis detection system includes a first subsystem configured to detect the presence of an infection in a patient, a second subsystem configured to detect the presence of a dysregulated immune response in the patient, a third subsystem configured to detect organ dysfunction in the patient, a fourth subsystem configured to detect antibiotic resistance (ARB) of a pathogen in the patient, and a processing device. The first, second, third, and fourth subsystems and the processing device are communicatively coupled to each other via a network. The processing device is configured to determine the presence of sepsis in the patient based on the presence of infection, the presence of the dysregulated host response, and clinical data indicative of organ dysfunction in the patient.The subsystems utilize at least one polymerase chain reaction (PCR) procedure, Raman spectroscopy, clinical data, electronic health record (EHR) data, and antibiotic susceptibility testing (antibiogram).

The disclosed invention is a method for mapping glutathione deficiency and / or mitochondria dysfunction in disease states, utilizing glutathione and its precursors as imaging tracers in conjunction with medical imaging techniques, particularly magnetic resonance imaging. The innovation involves administering glutathione or glutathione-increasing interventions, such as oral liposomal reduced glutathione, to enhance imaging accuracy. The proposed methodology aims to identify and monitor regions of depleted reduced glutathione (GSH) in various organs and tissues. The maps generated through this process provide valuable biomarkers for toxic exposure, early biological effects, and health risks. The approach is versatile, offering applications in mental health, neurological disorders, inflammation, organ dysfunction, and personalized treatment and risk assessments.

This invention relates to the field of multi-organ dysfunction (MOD) early warning technology, specifically to an MOD early warning method for patients with severe burns. The method includes the following steps: acquiring heart rate, mean arterial pressure, respiratory rate, blood oxygen saturation, lactate concentration, and urine output per unit time; calculating the rate of lactate change at adjacent time points to form a sequence; comparing the rate of change across time intervals to obtain the difference in change; combining heart rate and blood oxygen saturation to calculate circulatory load; and counting the number of early warning triggers that meet risk conditions. In this invention, by calculating the rate of change of lactate concentration at adjacent time points and combining it with interval direction statistics, tissue metabolic changes show trend characteristics; the rate of change of urine output combined with mean arterial pressure forms a record of renal perfusion changes, providing a continuous characterization of perfusion status; heart rate and blood oxygen saturation are used to calculate circulatory load; multiple physiological signals are linked for judgment; and recurring abnormalities are expressed through the number of triggers. This improves the stability and predictability of MOD risk identification in critically burned patients.

The invention belongs to the field of biological medicines, and particularly discloses application of extracellular vesicles EVs carrying CD35 functional molecules in preparation of medicines for treating sepsis-related multi-organ injury, preferably, the EVs are derived from human podocytes or other cells or tool cells capable of naturally or engineered expressing CD35, and the EVs are administrated through caudal vein injection and can be used for preparing medicines for treating sepsis-related multi-organ injury. Normal saline is taken as a carrier, and the dosage of 1 * 10 < 10 > EVs each time is once every 12 hours and twice continuously. It is proved for the first time that EVs carries CD35 to inhibit circulation mononuclear cell complement activation (the EVs are combined with C3b to block downstream complement cascade reaction), migration of mononuclear cells to the kidney, the heart, the liver and the lung is reduced, and therefore multi-organ inflammation damage and cell apoptosis are relieved. In a cecum ligation perforation (CLP) sepsis model, it is proved that the medicine significantly improves the survival rate of mice, improves renal functions (reduces creatinine / urea nitrogen) and kidney pathological tissue damage, and meanwhile relieves pathological damage of multiple organs of the heart, the liver and the lung. The invention provides a new treatment strategy and drug candidate for sepsis-related multi-organ dysfunction.

The invention belongs to the technical field of biotechnology and medicine, and particularly relates to application of an Anapc11 gene / protein to screening of drugs for treating hyperuricemia-related multi-organ dysfunction. According to the invention, the Anapc11 gene is used as a molecular target or a drug action target, and is used for screening or preparing drugs for treating multi-organ dysfunction (including liver injury, testis dysfunction, intestinal barrier destruction and the like) caused by hyperuricemia. The invention provides a new application of the cell cycle promoting complex subunit E3 ubiquitin ligase Anapc11 gene, provides a new molecular target for treating hyperuricemia related multi-organ dysfunction, and breaks through the limitation that the existing uric acid reducing medicine is only limited to a metabolic link; a new direction and a good application prospect are provided for developing innovative medicines with organ protection effects.

The invention belongs to the technical field of sepsis treatment, and particularly relates to application of a preparation for preventing ENO1 from playing a glycolysis role in preparing a medicine for treating sepsis. It is found for the first time that promotion of interaction of IL1R2-ENO1 can inhibit the glycolysis level of macrophages, significantly inhibit pyroptosis of macrophages induced by LPS + ATP, inhibit generation of inflammatory mediators IL1beta and the like, relieve dysfunction of multiple organs and significantly improve the survival rate of mice, and it is also found that AP-III-a4 is a non-substrate analogue inhibitor of ENO1 and can inhibit the glycolysis ability of ENO1 after being combined with ENO1. Therefore, IL1R2 and AP-III-a4 can be used as a promising treatment target for treating sepsis when being used for preventing the ENO1 from playing a glycolysis role.

The invention relates to the technical field of biological medicines, in particular to application of EGCG (epigallocatechin gallate) and a preparation thereof in inhibiting vibrio vulnificus or diseases caused by the vibrio vulnificus. It is found for the first time that EGCG can inhibit growth of vibrio vulnificus, destroy cell membranes of the vibrio vulnificus and inhibit formation of mycoderm, meanwhile, TLR4, MyD88 and / or NF-kappa B signal channels can be adjusted, host inflammatory response and organ dysfunction are relieved, and therefore EGCG can be used for preventing and / or treating vibrio vulnificus sepsis caused by the vibrio vulnificus; the blank of the existing treatment means in the aspect of anti-vibrio vulnificus and immune double-target intervention is filled, and important theoretical significance and application prospects are achieved.

The present invention relates to the technical field of genetically engineered mouse models, and specifically to a Kdf1 gene conditional knockout mouse model and a construction method thereof. The construction method comprises the following steps performed in sequence: obtaining a donor vector; obtaining gRNA; obtaining a conditional knockout mouse model capable of accurately knocking out the Kdf1 gene. The present technical solution solves the technical problem that it is difficult to accurately study the mechanism of Kdf1 regulating organ development using the Kdf1 gene functional defect mouse model of the prior art. The mouse model of the present solution can be mated and propagated with Cre mice from a variety of tissue sources, thereby constructing a mouse model of Kdf1 gene knockout with multiple tissue specificities that can be stably propagated, thereby avoiding embryonic lethality caused by systemic organ dysfunction in mice, and at the same time, the Kdf1 gene of the tooth germ epithelial tissue can be specifically knocked out, creating conditions for studying the function of the Kdf1 gene.

The present invention provides an anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold for use in the treatment of a chronic or acute disease or acute condition in a patient to prevent or reduce organ dysfunction or organ failure. In a preferred embodiment, the invention provides an anti-ADM antibody or an anti-adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold for use in the treatment of a chronic or acute disease or acute condition in a patient to prevent or reduce renal dysfunction or renal failure or hepatic dysfunction or hepatic failure.

The compositions and methods of use disclosed herein include compositions and methods of use for treating or preventing sepsis in subjects in need thereof, the methods including methods of extending the survival of subjects with sepsis and reducing organ dysfunction or failure caused by sepsis. The methods of treating or preventing sepsis in subjects in need thereof include administering a composition comprising early apoptotic cells or early apoptotic cell supernatants. The compositions and methods of use thereof can reduce the negative pro-inflammatory effects associated with sepsis. Further, anti-inflammatory cytokine release can be reduced. In some cases, the compositions can include additional agents.

This invention provides the application of baicalin in the preparation of drugs antagonizing jellyfish toxin lethality, belonging to the field of pharmaceutical technology. Experiments have verified that baicalin can alleviate multi-organ dysfunction caused by jellyfish stings. Cell experiments show that baicalin can significantly increase the proliferation rate of RAW 264.7 cells and antagonize jellyfish toxin-induced apoptosis; mouse experiments show that baicalin can significantly improve mouse survival rate and alleviate the damage to the heart, liver, and kidneys caused by jellyfish toxin.

The invention discloses a sepsis organ dysfunction early warning method based on sparse data incremental coding, and the method comprises the steps: obtaining event sequence data and non-event sequence data of a target object, the event sequence data comprising at least one of clinical diagnosis data, treatment record data and laboratory historical detection data, and the non-event sequence data comprising at least one of the clinical diagnosis data, the treatment record data and the laboratory historical detection data; the non-event sequence data at least comprises past medical history data and target sign data; performing incremental coding on the event sequence data to obtain a sparse mode of the event sequence data; processing the sparse mode, the event sequence data and the non-event sequence data according to a pre-constructed early warning model to obtain sepsis risk indexes of the target object; and under the condition that the sepsis risk index meets a preset early warning condition, outputting target early warning information.

The present invention relates to metal nanoparticles and a plasmonic biosensor including the same. According to the present invention, it is possible to provide novel metal nanoparticles having significantly improved sensitivity to light, and further, it is possible to provide a plasmonic biosensor capable of detecting a trace amount of a biomarker present in a biological sample with high precision through the metal nanoparticles. In addition, the plasmonic biosensor is capable of detecting a sepsis biomarker with high sensitivity and specificity, and thus may be usefully used in various clinical applications such as sepsis diagnosis, identification of the type of organ dysfunction, prediction of sepsis severity, and post-treatment.

Sickle cell disease (SCD) is a single gene disorder characterized by mutant hemoglobin-S (HbS) and chronic intravascular haemolysis. Painful vaso-occlusive crises (VOC) are typical of SCD and often associated to a further rise in hemolysis. VOC is the clinically painful form of vaso-occlusion, that is due to the aggregation of red blood cells in the capillaries and venules. Such event is promoted or aggravated by adhesion of polymorphonuclear neutrophils (PMNs) to red blood cells and the endothelium leading to tissue ischemia, inflammation and imperfect repair. Repeated vaso-occlusion and PMNs interactions with the vascular endothelium are thought to promote microvascular injuries in SCD patients. The inventors tested the effect of pharmacological inhibition of TREM-1 with LR12 peptide in two experimental vaso-occlusive crisis models. Additional validation of TREM-1 involvement in vaso-occlusion was verified using mice with sickle cell disease and Trem-1 gene deficiency. In particular, the inventors showed that TREM-1 inhibition is particular suitable for limiting the severity of vaso-occlusions. The results obtained by the inventors also suggest that plasmatic concentration of sTREM-1 could be a reliable biomarker for predicting vaso-occlusions and / or SCD-associated organ dysfunction and end-organ damage.

The invention discloses an application of an ester compound in preparation of a sepsis prevention and treatment medicine. The structural formula of the ester compound is as shown in the following formula: # imgabs0 #. The compound can relieve multi-organ injury caused by sepsis, relieve organ dysfunction caused by sepsis and reduce release of inflammatory factors and injury factors, and can be used for preventing, relieving and / or treating sepsis and other related diseases and improving sepsis organ injury and inflammatory response.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for treating acute lung injury and a preparation method and application thereof. The traditional Chinese medicine composition for treating the acute lung injury is prepared from the following raw materials in parts by weight: 10 to 15 parts of cortex moutan, 15 to 25 parts of radix paeoniae rubra, 25 to 35 parts of radix rehmanniae recen, 10 to 20 parts of semen persicae, 10 to 20 parts of fructus aurantii immaturus, 10 to 15 parts of radix curcumae, 10 to 15 parts of rhizoma acori graminei, 15 to 25 parts of fructus trichosanthis, 10 to 20 parts of fructus forsythiae, 10 to 20 parts of rhizoma polygoni cuspidati, 15 to 25 parts of semen lepidii and 25 to 35 parts of radix astragali seu hedysari. The traditional Chinese medicine composition has the beneficial effects that the traditional Chinese medicine composition for treating the acute lung injury can play a role in the aspects of improving the immune state, improving circulation and the like by influencing the release of inflammatory factors; the traditional Chinese medicine composition can improve the treatment effective rate and off-line success rate of acute lung injury patients, shorten the mechanical ventilation time, improve the oxygenation index of the patients, reduce the expression of proinflammatory factors IL-6, regulate the immune balance of Th1 / Th2 and Th17 / Treg, improve hemagglutination and relieve the disease severity and multi-organ dysfunction of the patients.

A method of reducing the risk of a sepsis-induced vascular leak, tissue edema or organ dysfunction is provided. The method involves administering an effective amount of a composition selected from the group consisting of Lipocalin 10 (SEQ ID NO: 1), a truncated Lipocalin 10 (Lcn10) protein having the amino acid sequence SEQ ID NO: 2, Lcn 10-expressing vectors for full length / truncated Lcn10, or combinations thereof to the subject, The method is also useful for reducing the risk of a heart attack-induced cardiac dysfunction, atherosclerosis, inflammatory bowel disease or diabetes-induced cardiomyopathy.

The invention discloses a traditional Chinese medicine composition for preventing and treating sepsis microcirculation and blood coagulation dysfunction. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 20-40 parts of ginseng, 5-15 parts of rheum officinale, 20-40 parts of sargentgloryvine stem, 20-40 parts of dandelion, 20-40 parts of radix aconiti carmichaeli and 2-8 parts of leech. The traditional Chinese medicine composition has the effects of supporting the healthy energy, clearing away heat and toxic materials and promoting blood circulation to remove blood stasis, clinical tests show that the traditional Chinese medicine composition can remarkably improve microcirculation disturbance and blood coagulation dysfunction of a sepsis patient, reduce the 28-day full-cause case fatality rate of the patient, improve multi-organ dysfunction and relieve inflammatory response for the yang-deficiency and toxin-stasis type sepsis patient, and has good safety. In addition, the invention further discloses a preparation method and application of the traditional Chinese medicine composition.

The present invention relates to in vitro methods for prognosing the outcome of an organ dysfunction in a patient, in vitro methods for diagnosing the degree of severity of an organ dysfunction in a patient and in vitro methods for diagnosing the presence of an organ dysfunction in a subject, wherein said in vitro methods comprise a step of determining the level of mature and / or active mitochondrial transcription factor A (TFAM) protein in a sample. Furthermore, the invention relates to methods of treating a patient in need suffering from an organ dysfunction and methods of treating a patient in need suffering from an infection and / or inflammation. Furthermore, the invention relates to a binding molecule specifically binding the mature and / or active TFAM protein, a binding molecule specifically binding the immature TFAM protein and a kit comprising (i) a primary binding molecule specifically binding TFAM protein and / or (ii) a primary binding molecule specifically binding TFB2M, and to uses of said binding molecules and kit. Furthermore, the invention relates to a method for identifying a compound which promotes the transport of TFAM protein into mitochondria and / or which promotes the maturation of TFAM protein and compounds identified by such a method.

The present application belongs to the field of biotechnology and medical technology, and particularly relates to Anapc11 gene / protein for screening drugs for treating hyperuricemia related multi-organ dysfunction. The present application uses Anapc11 gene as a molecular target or a drug action target for screening or preparing drugs for treating multi-organ dysfunction caused by hyperuricemia (including liver injury, testicular dysfunction and intestinal barrier damage). The present application provides a new use of cell cycle promoting complex subunit E3 ubiquitin ligase Anapc11 gene, provides a new molecular target for treating hyperuricemia related multi-organ dysfunction, breaks the limitation of existing uric acid lowering drugs only in the metabolic link, and provides a new direction and good application prospect for developing innovative drugs with organ protection effect.

A system and method is disclosed for measuring muscle reflexes (e.g., a bulbocavernosus reflex) as a tool for identifying / diagnosing dysfunctions (e.g., spinal cord abnormalities, bladder voiding dysfunction, and sexual organ dysfunction) non-invasively by using mechanical stimulation. The system and method includes a probe having a predetermined patient contacting portion, wherein when the contacting portion is moved into contact with a particular area of the patient (e.g., the patient's genitals), the contact induces a muscle reflex. The probe detects the pressure resulting from the contacting portion being abruptly and forcibly brought into contact with the particular area. Such detection is used to electronically initiate capture of electrical responses from a plurality of electrodes placed on the patient's skin in proximity to the particular area. Such electrical responses are processed to determine characteristics of the patient's reflexes of one or more muscles adjacent to thh: \e electrodes.

The invention discloses application of a compound in preparation of a medicine for preventing or treating sepsis. Research finds that the compound provided by the invention can improve the survival rate of sepsis patients, improve organ injury caused by sepsis and relieve organ dysfunction caused by sepsis. Besides, multiple experiments prove that the compound has excellent stability and reproducibility, so that the compound can be used for preparing medicines or health-care products for preventing, improving or treating sepsis.

The invention provides a traditional Chinese medicine composition for treating exogenous headache and a preparation method thereof, and belongs to the technical field of traditional Chinese medicinal materials. The traditional Chinese medicine raw material formula contains 6-20 parts by weight of radix puerariae, 1-5 parts by weight of fructus viticis, 1-5 parts by weight of rhizoma corydalis, 4-16 parts by weight of mint, 4-20 parts by weight of ligusticum wallichii, 4-20 parts by weight of schizonepeta, 1-5 parts by weight of asarum, 1-10 parts by weight of radix saposhnikoviae, 3-10 parts by weight of radix angelicae, 3-10 parts by weight of notopterygium root and 3-10 parts by weight of honey-fried licorice root. Traditional medicine believes that headache is mainly caused by internal organ dysfunction due to wind-cold damp evil invasion, emotion depression, improper diet and the like, exogenous evil invading brain collaterals, blood stasis and stagnation, and pain due to obstruction. The disease is treated according to the principle of dispelling wind, relieving pain and promoting blood circulation to remove blood stasis. The traditional Chinese medicine composition prepared by the method disclosed by the invention can dispel wind, dredge collaterals, dispel cold, eliminate dampness, clear head and eyes, promote qi circulation and relieve pain by matching the 11 traditional Chinese medicines.

This invention belongs to the field of smart healthcare and digital health technology, providing a method and platform for intelligent monitoring and early warning of health risks for people with chronic diseases. The method includes: collecting physiological indicators, lifestyle habits, and traditional Chinese medicine constitution identification information, and fusing them to generate multi-dimensional time-series data on chronic disease characteristics; constructing and dynamically updating a personal dynamic health model; establishing a three-tiered progressive early warning mechanism of L1-level trend deviation, L2-level organ dysfunction, and L3-level complication risk, clarifying the triggering conditions for each level of early warning; based on the early warning level, calling upon a knowledge base of traditional Chinese and Western medicine intervention rules to generate and push personalized intervention plans; collecting feedback data to optimize the model and evaluate the intervention effect. The platform includes a smart terminal layer, a platform service layer, a model knowledge base, and an application interaction layer, adopting an edge-cloud collaborative architecture to improve monitoring real-time performance. This invention, through multi-dimensional data fusion and hierarchical early warning, can achieve early identification and accurate early warning of chronic disease risks.

The present invention refers to an oligonucleotide comprising 15 to 22 nucleotides, wherein at least one of the nucleotides is modified, and the oligonucleotide hybridizes with pre-mRNA of mixed lineage kinase domain like pseudokinase (MLKL) derived from SEQ ID NO.1289 (GRCh38.p 14: 16:74671855-74700960) or mRNA of MLKL derived from SEQ ID NO.1290 (RefSeq ID NM_152649.4). The invention is further directed to a pharmaceutical composition comprising such oligonucleotide. The pharmaceutical composition and the oligonucleotide are for use in a method of preventing and / or treating a hyperproliferative disorder, an inflammatory or autoimmune disorder, neurodegenerative disease, a neurological disorder, cardiovascular, metabolic disorder, renal disorder, liver disorder, lung disorder, skin disorder, ocular disorder, disorder of the gastro-intestinal tract, joint inflammation, organ malfunction after organ transplantation, fibrotic disorder and a combination thereof inflammatory disease, cancer, an ophthalmic disease, an autoimmune disorder and / or an immune disorder.

The invention discloses an intelligent early warning system for cardiac intensive care, and the system comprises a treatment input module which is used for receiving the input parameters of a cardiac treatment drug and basic physical sign data of a patient; the data real-time acquisition module is used for acquiring ECG data, kidney marker data and respiratory function data of a patient; the exception handling module is configured to output a causal effect estimated value and an exception probability value through a pre-trained DML model, and output predicted concentration of a preset marker and predicted data of preset function data through a pre-trained NODE model; and the closed-loop control module is used for updating the pre-trained DML model and the pre-trained NODE model. Therefore, on one hand, heart treatment drug-related and non-drug-related sexual organ dysfunction can be accurately distinguished, clinical misjudgment is avoided, on the other hand, continuous time trajectory prediction of kidney and respiratory function indexes can be realized, and potential abnormality can be warned in advance.